Login to Your Account

Melanoma Space Changing

Plexxikon's Speedy Zelboraf Work Helped by Diagnostic

By Jennifer Boggs

Thursday, August 18, 2011
Given the hoopla surrounding data for Plexxikon Inc.'s targeted melanoma candidate Zelboraf (vemurafenib) earlier this year, a sooner-than-expected FDA nod for the drug and its companion diagnostic in patients with a specific BRAF mutation came as little surprise.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription